Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: A prospective analysis

Cancer

Volumn 110, Issue 9, 2007, Pages 1945-1950

  Kuebler, J Philip ^a,b   Colangelo, Linda ^a   O'Connell, Michael J ^a   Smith, Roy E ^c   Yothers, Greg ^a   Begovic, Mirsada ^a   Robinson, Bridget ^d   Seay, Thomas E ^e   Wolmark, Norman ^a,f  

^a NSABP Foundation Inc   (United States)

^b Department of Hematology Oncology   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

^e Atlanta Cancer Care   (United States)

^f ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Adjuvant therapy; Chemotherapy; Colon cancer; Diarrhea; Enteropathy; Fluorouracil; Leucovorin; Oxaliplatin

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; FLUOROURACIL; FOLINIC ACID; OCTREOTIDE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE INJURY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEX DIFFERENCE; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC DISEASES; COLONIC NEOPLASMS; DIARRHEA; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SEX FACTORS;

EID: 35648976653     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23013     Document Type: Article

References (20)

1. NCCN Practice Guidelines in Oncology-v.2.2006. Available at URL: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf Accessed on January 18, 2007.
2. Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J Supp Oncol. 2003;1:35-46.
3. O'Brien BE, Kaklamani VG, Benson AB 3rd. The assessment and management of cancer treatment-related diarrhea. Clin Colorectal Cancer. 2005;4:375-381.
4. Smith RE, Colangelo L, Wieand S, et al. The occurrence of severe enteropathy among patients with stage II/III resected colon cancer (CC) treated with 5-fluorouracil/leucovorin (FL) plus oxaliplatin (FLOX) [abstract]. Proc Am Soc Clin Oncol. 2003:22. Abstract 1181.
5. Takaoka E, Kawal K, Ando S, et al. Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer. Jpn J Clin Oncol. 2006;36:60-63.
6. Wenzel C, Urbauer E, Schwarz C, et al. Severe enteropathy associated with ralitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event. Anticancer Drugs. 2006;17:865-868.
7. Avigan D, Richardson P, Elias A, et al. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series of a review of the literature. Cancer. 1998;83:409-414.
8. Tham RT, Vlasveld LT, Willemze R. Gastrointestinal complications of cytosine-arabinoside chemotherapy: findings on plain abdominal radiographs. AJR Am J Roentgenol. 1990;154:95-98.
9. Zamani R, Heldmann M. Enteritis as a complication of adjuvant combination chemotherapy using 5-fluorouracil and leukovorin: clinical and helical computed tomographic features. J La State Med Soc. 2004;156:143-144.
10. Kelvin FM, Gramm HF, Gluck WL, et al. Radiologic manifestations of small bowel toxicity due to floxuridine therapy. AJR Am J Roentgenol. 1986;146:39-43.
11. Hiehle JF Jr, Levine MS. Gastrointestinal toxicity of 5-FU and 5-FUDR: radiographic findings. Can Assoc Radiol J. 1991;42:109-112.
12. Fata F, Ron IG, Kemeny N, et al. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer. 1999;86:1129-1134.
13. Dranitsaris G, Maroun J, Shah A. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can J Gastroenterol. 2005;19:83-87.
14. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol. 1987;5:1559-1565.
15. Chou CK. CT manifestations of bowel ischemia. AJR Am J Roentgenol. 2002;178:87-91.
16. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20:1491-1498.
17. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103:1165-1171.
18. Kuebler P, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer. Results from NSABP protocol C-07. J Clin Oncol. 2007;25:2198-2204.
19. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
20. Rosenoff S. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Support Care Cancer. 2004;12:561-570.